



FOR IMMEDIATE RELEASE

Contact:

Reinier Schwieter
Vice President of Global Marketing
QPS Holdings, LLC
Delaware Technology Park
3 Innovation Way, Suite 240
Newark, DE 19711
USA

+31 (50) 304 8003
reinier.schwieter@qps.com

QPS Announces the Opening of its New *In Vitro* Dermal & Transdermal Research Laboratory in Fargo, North Dakota

(Newark, DE; May 6, 2015) – QPS Holdings, LLC, a leading full-service contract research organization, announces the opening of its new *in vitro* dermatology and transdermal research laboratory in Fargo, North Dakota. This new physical extension of QPS’ Dermal and Transdermal Research Services portfolio will further strengthen QPS’ ability to assist clients in quickly moving their dermal and transdermal products from pre-clinical evaluations through to late stage clinical development.

“With QPS’ increasing early phase clinical presence in topical and transdermal pharmacokinetics and bioequivalence, this is a logical step in the evolution of our Dermal and Transdermal Research Services Division,” said Ben Chien, PhD, QPS President and CEO. “Our Dermal and Transdermal Research Services Division, which has been embraced by the industry since its establishment under the leadership of Paul Lehman, has quickly become a major asset to QPS—and crucial for the future success for our clients.”

The laboratory will be directed by Paul A. Lehman, MSc, Vice President and Head of QPS Dermal and Transdermal Research Services. This research facility is backed by 36 years of topical pharmacokinetics experience with the Franz Diffusion Cell. This model and associated methodologies support dermal drug development testing in the preclinical, clinical, and post-approval phases, including the *in vitro* rate-of-release assay based on the FDA SUPAC-SS Guidance.

As of May 1st, 2015 the new *in vitro* dermatology and transdermal laboratory in Fargo, North Dakota is offering its services to clients conducting *in vitro* Research & Development (non-GLP) topical pharmacokinetics and *in vitro* release rate studies using the Franz Diffusion Cell. The laboratory will also be offering augmenting services for studies intended for regulatory submission (with full GLP compliance).

About QPS

QPS is a GLP/GCP-compliant CRO that supports discovery, and preclinical and clinical drug development. We provide quality services in Neuropharmacology, Drug Metabolism and Pharmacokinetics, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development to clients worldwide. Our 30+ regional laboratories, clinical facilities and offices are located in North America, Europe, India and Asia. For more information, visit <http://www.qps.com> or contact Mariya Rzaszutak, Director Business Development for Generic, Dermal & Transdermal services at mariya.rzaszutak@qps.com.